Meridian Bioscience (NASDAQ:VIVO) Downgraded to Hold at StockNews.com
Meridian Bioscience (NASDAQ:VIVO) Downgraded to Hold at StockNews.com
StockNews.com downgraded shares of Meridian Bioscience (NASDAQ:VIVO – Get Rating) from a buy rating to a hold rating in a research report sent to investors on Tuesday morning.
在周二上午发给投资者的一份研究报告中,斯托克新闻网将默里迪安生物科学公司(纳斯达克:VIVO-GET Rating)的股票评级从买入下调至持有。
VIVO has been the topic of a number of other reports. HC Wainwright cut shares of Meridian Bioscience from a buy rating to a neutral rating and boosted their target price for the company from $30.00 to $34.00 in a research note on Friday, July 8th. William Blair downgraded Meridian Bioscience from an outperform rating to a market perform rating in a research report on Thursday, July 7th.
VIVO一直是其他一些报道的主题。在7月8日星期五的一份研究报告中,HC Wainwright将Meridian Bioscience的股票评级从买入下调至中性,并将该公司的目标价从30.00美元上调至34.00美元。在7月7日星期四的一份研究报告中,威廉·布莱尔将子午线生物科学公司的评级从跑赢大盘下调至市场表现。
Meridian Bioscience Stock Performance
子午线生物科学股票表现
Shares of Meridian Bioscience stock opened at $32.71 on Tuesday. The firm has a market capitalization of $1.43 billion, a P/E ratio of 33.04 and a beta of 0.28. The company has a current ratio of 3.52, a quick ratio of 2.60 and a debt-to-equity ratio of 0.07. The business's fifty day simple moving average is $30.99 and its 200 day simple moving average is $27.48. Meridian Bioscience has a 12 month low of $17.20 and a 12 month high of $34.38.
子午线生物科学公司的股票周二开盘报32.71美元。该公司的市值为14.3亿美元,市盈率为33.04倍,贝塔系数为0.28。该公司的流动比率为3.52,速动比率为2.60,债务权益比率为0.07。该业务的50日简单移动均线切入位为30.99美元,200日简单移动均线切入位为27.48美元。Meridian Bioscience的12个月低点为17.20美元,12个月高位为34.38美元。
Insider Buying and Selling
内幕买卖
Institutional Investors Weigh In On Meridian Bioscience
机构投资者看好子午线生物科学
Institutional investors and hedge funds have recently bought and sold shares of the stock. FMR LLC raised its position in shares of Meridian Bioscience by 218.6% during the 2nd quarter. FMR LLC now owns 1,950,987 shares of the company's stock valued at $59,350,000 after buying an additional 1,338,620 shares in the last quarter. Epoch Investment Partners Inc. bought a new stake in Meridian Bioscience during the fourth quarter worth about $14,348,000. Fuller & Thaler Asset Management Inc. boosted its holdings in shares of Meridian Bioscience by 129.1% in the 4th quarter. Fuller & Thaler Asset Management Inc. now owns 455,665 shares of the company's stock worth $9,296,000 after purchasing an additional 256,729 shares in the last quarter. Fort Washington Investment Advisors Inc. OH increased its position in shares of Meridian Bioscience by 44.6% during the 1st quarter. Fort Washington Investment Advisors Inc. OH now owns 640,418 shares of the company's stock valued at $16,625,000 after purchasing an additional 197,550 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Meridian Bioscience by 10.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,031,764 shares of the company's stock valued at $61,806,000 after buying an additional 197,000 shares in the last quarter. 94.72% of the stock is owned by hedge funds and other institutional investors.
机构投资者和对冲基金最近买卖了该股的股票。FMR LLC在第二季度将其在子午线生物科学公司的股票头寸提高了218.6%。FMR LLC现在拥有1,950,987股该公司股票,价值59,350,000美元,上个季度又购买了1,338,620股。Epoch Investment Partners Inc.在第四季度购买了Meridian Bioscience的新股份,价值约14,348,000美元。富勒资产管理公司(Fuller&Thaler Asset Management Inc.)在第四季度将其持有的子午线生物科学公司的股票增加了129.1%。富勒资产管理公司(Fuller&Thaler Asset Management Inc.)目前持有该公司455,665股股票,价值9,296,000美元,上个季度又购买了256,729股。第一季度,华盛顿堡垒投资顾问公司(Fort Washington Investment Advisors Inc.)增持Merdian Bioscience股票的头寸增加了44.6%。华盛顿堡投资顾问公司(Fort Washington Investment Advisors Inc.)目前持有该公司640,418股票,价值16,625,000美元,此前该公司在上个季度又购买了197,550股票。最后,复兴科技有限责任公司在第二季度将其持有的子午线生物科学公司的股票增加了10.7%。复兴科技有限责任公司现在拥有该公司2,031,764股股票,价值61,806,000美元,上个季度又购买了197,000股。94.72%的股票由对冲基金和其他机构投资者持有。
Meridian Bioscience Company Profile
子午线生物科学公司简介
(Get Rating)
(获取评级)
Meridian Bioscience, Inc, a life science company, develops, manufactures, distributes, and sells diagnostic test kits primarily for gastrointestinal and respiratory infectious diseases, and elevated blood lead levels worldwide. The company operates through Diagnostics and Life Science segments. The Diagnostics segment offers testing platforms, including real-time PCR amplification under the Revogene brand; isothermal DNA amplification under the Alethia brand; lateral flow immunoassay using fluorescent chemistry under the Curian brand; rapid immunoassay under the ImmunoCard and ImmunoCard STAT! brands; enzyme-linked immunoassays under the PREMIER brand; anodic stripping voltammetry under the LeadCare brands; and urea breath testing for H.
Meridian Bioscience,Inc.是一家生命科学公司,主要开发、制造、分销和销售诊断试剂盒,主要用于胃肠道和呼吸道传染病以及全球范围内的血铅水平升高。该公司通过诊断和生命科学部门开展业务。诊断部门提供测试平台,包括Revogene品牌下的实时PCR扩增;Alethia品牌下的等温DNA扩增;Curian品牌下使用荧光化学的侧向流动免疫分析;免疫卡和免疫卡STAT下的快速免疫分析!品牌;Premier品牌的酶联免疫检测;LeadCare品牌的阳极溶出伏安法;以及H.
See Also
另请参阅
- Get a free copy of the StockNews.com research report on Meridian Bioscience (VIVO)
- MarketBeat: Week in Review 8/8 – 8/12
- 2 Important Retail Stock Battles to Watch
- What Is WallStreetBets and What Stocks Are They Targeting?
- Institutions And Analysts Propel Jack In The Box Higher
- Can You Guess Which EV Stock Is Beating Tesla ?
- 免费获取StockNews.com关于子午线生物科学的研究报告(Vivo)
- MarketBeat:回顾中的一周2012-8-8
- 值得关注的两场重要的零售股大战
- 什么是WallStreetBets,他们的目标是什么股票?
- 机构和分析师推动Jack in the Box走高
- 你能猜到哪个电动车股票打败了特斯拉吗?
Receive News & Ratings for Meridian Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Meridian Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
接受《子午线生物科学日报》的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯,接收对Meridian Bioscience和相关公司的最新新闻和分析师评级的每日简要摘要。